Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorKuirong Jiang
About this trial
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Eligibility criteria
Qualifiers
ECOG performance status 0 or 1.
Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
ECOG performance status 0 or 1.
Life expectancy of greater than or equal to 6 months.
Disqualifiers
Patients who cannot eat orally and have gastric emptying disorder after surgery;
Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;
Patients who cannot eat orally and have gastric emptying disorder after surgery;
Patients who cannot eat orally and have gastric emptying disorder after surgery;
Trial design
Treatments tested in this trial
- Irinotecan liposome injection
Treatment groups
53 Participants
are divided into 1 treatment groupSponsors and collaborators
Kuirong Jiang
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Sponsor institution
CSPC Ouyi Pharmaceutical Co., Ltd.
Collaborator
Source ClinicalTrials.gov